1. Adachi, J., Naito, T., Ueno, Y., Ogawa, Y., Ninomiya, I., Tatsuno, Y., 1993, Metabolism and distribution in the rat of the peak E substance, a constituent in L-trytophan product implicated in eosinophilia-myalgia syndrome. Arch Toxicol67 (4): 284
2. Ascher, P., Henderson, G., Johnson, J.W., 1988, Dual inhibitory actions of kynurenate on the N-methyl-o-aspartate (NMDA)-activated response of cultured mouse cortical neurons. J Physiol406: 141
3. Bono, G., Micieli, G., Sances, G., Calvani, M., Nappi, G., 1984, L-5HTP treatment in primary headaches: an attempt at clinical identification of responsive patients. Cephalalgia4: 159
4. Del Bianco, P.L., Franchi, G., Anselmi, B., Sicuteri, F., 1982, Monoamine sensitivity of smooth muscle in vivo in nociception disorders, in: “Advances in Neurology”, M. Critchley, AP. Friedman, S. Gorini, F. Sicuteri, eds, Raven Press, New York
5. Donofrio, P.D., Stanton, C., Miller, V.S., Oestreich, L., Lefkowitz, D.S., Walker, F.O., Ely, E.W., 1992, Demyelinating polyneuropathy in eosinophilia-myalgia syndrome. Muscle Nerve15 (7): 796